Intellia Therapeutics, Inc.
About
14.07USD+0.39 +2.85%
Closed • Updated at 02:39 GMT+00:00Market Cap$1.97B
Volume5.54M
Beta1.42
RSI55.28
Gross Margin76.32%
Intellia Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 11 2026
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Apr 27 2026
Intellia Announces Proposed Public Offering of Common Stock
Apr 27 2026
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Apr 27 2026
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Apr 24 2026
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Recent Videos
Beam Therapeutics BEAM Stock Analysis 1080p caption #space #marketupdate #stocks
May 15, 2026
NTLA Intellia Therapeutics Stock Analysis 1080p caption #marketupdate #space #stocks $NTLA
May 15, 2026
CRISPR History Made! Intellia's 87% Cure Rate & $145 Fair Value? #NTLA #IntelliaTherapeutics #CRISPR
May 12, 2026
Trending in Rare Diseases: Intellia BLA, Tavneos Withdrawal and more
May 08, 2026
Community Chat
Ask AI
Try asking